胸部肌少症是晚期非小细胞肺癌免疫治疗患者的不良预后预测因素
该回顾性研究纳入242例接受免疫治疗的晚期非小细胞肺癌患者,在治疗前胸部CT的第五胸椎(T5)水平测量骨骼肌横截面积,以性别特异性最低四分位值定义肌少症。发现队列中肌少症患者无进展生存期显著更差(p < 0.001),基于肌少症等参数构建的随机生存森林模型预测6个月和12个月无进展生存期的AUC分别为0.68和0.69,验证队列表现相似。结论认为T5水平肌少症是独立预后因素。
要点
- 治疗前胸部CT T5水平可评估肌少症,无需腹部影像。
- 肌少症与晚期NSCLC免疫治疗患者更差的无进展生存期独立相关。
- 基于肌少症等参数的模型预测6个月和12个月PFS的AUC分别为0.68和0.69。
核心结论
- T5水平肌少症是接受免疫治疗的晚期非小细胞肺癌患者的独立预后因素。
研究设计与样本
- 回顾性研究,纳入2019年至2022年接受免疫治疗的晚期NSCLC患者242例(发现队列194例,验证队列48例),在治疗前胸部CT的T5水平计算横截面骨骼肌面积,以性别特异性最低四分位值定义肌少症,采用Cox分析、log-rank检验和随机生存森林模型进行分析。
关键影像表现/征象
- 在治疗前胸部CT第五胸椎(T5)水平计算横截面骨骼肌面积,以性别特异性最低四分位值定义肌少症。
诊断标准与关键数值
- 肌少症定义为T5水平横截面骨骼肌面积的性别特异性最低四分位值。
- 发现队列中肌少症患者无进展生存期显著差于无肌少症患者(p < 0.001)。
- 单因素Cox回归显示肌少症、肺癌分期、体重指数、吸烟状态和中性粒细胞与淋巴细胞比值是较差无进展生存期的预测因素。
- 随机生存森林模型预测6个月无进展生存期的AUC为0.68,预测12个月无进展生存期的AUC为0.69。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Sarcopenia, as measured at the level of the third lumbar (L3) has been shown to predict the survival of cancer patients. However, many patients with advanced non-small cell lung cancer (NSCLC) do not undergo routine abdominal imaging. The objective of this study was to investigate the association of thoracic sarcopenia with survival outcomes among patients who underwent immunotherapy for NSCLC.
MATERIALS AND METHODS: In this retrospective study, patients who initiated immunotherapy for advanced NSCLC from 2019 to 2022 were enrolled. and detailed patient data were collected. Cross sectional skeletal muscle area was calculated at the fifth thoracic vertebra (T5) on pretreatment chest computed tomography (CT) scan. Gender-specific lowest quartile values was used to define sarcopenia. The risk factors were analyzed using Cox analyses. The log-rank test and the random survival forest (RSF) were used to compare progression free survival (PFS). The model's performance was assessed using calibration curve and the receiver operating characteristic curve (ROC).
RESULTS: A total of 242 patients was included (discovery cohort n = 194, validation cohort n = 48). In the discovery cohort, patients with sarcopenia exhibited significantly poorer PFS (p < 0.001) than patients without sarcopenia. Univariate cox regression revealed that sarcopenia, lung cancer stage, body mass index, smoking status, and neutrophil-to-lymphocyte ratio were predictors of poor PFS. A RSF model was constructed based on the aforementioned parameters, to evaluate the model's efficacy, the ROC curve was utilized. with an area under the curve for predicting 6-month PFS of 0.68 and for 12-month PFS of 0.69. The prediction models for survival outcomes built by the discovery cohort showed similar performance in the validation cohort.
CONCLUSION: Sarcopenia at T5 is independent prognostic factors in patients who received immunotherapy for advanced NSCLC.
引用
- Wang M, Yang P, Zhou L, et al. Thoracic Sarcopenia was a Poor Prognostic Predictor in Patients Receiving Immunotherapy for Advanced Non-small-cell Lung Cancer. Acad Radiol. 2024. PMID: 39181824. doi:10.1016/j.acra.2024.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。